INS and type 2 diabetes mellitus: The most recent randomized, double-blind, parallel-group, Phase 3 DINAMO trial assessed the efficacy and safety of empagliflozin versus placebo on glycemic control in children and adolescents with T2D who had been previously treated with metformin or insulin.